Welcome to LookChem.com Sign In|Join Free

CAS

  • or

51334-86-2

Post Buying Request

51334-86-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

51334-86-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 51334-86-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,1,3,3 and 4 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 51334-86:
(7*5)+(6*1)+(5*3)+(4*3)+(3*4)+(2*8)+(1*6)=102
102 % 10 = 2
So 51334-86-2 is a valid CAS Registry Number.

51334-86-2 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Aldrich

  • (548820)  4-(4-Chlorophenyl)-1-(2H)-phthalazinone  97%

  • 51334-86-2

  • 548820-25G

  • 1,819.35CNY

  • Detail

51334-86-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-(4-chlorophenyl)-2H-phthalazin-1-one

1.2 Other means of identification

Product number -
Other names 4-(4-Chlor-phenyl)-2H-phthalazin-1-on

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:51334-86-2 SDS

51334-86-2Relevant articles and documents

Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells as apoptosis-inducing agents

Eldehna, Wagdy M.,Almahli, Hadia,Al-Ansary, Ghada H.,Ghabbour, Hazem A.,Aly, Mohamed H.,Ismael, Omnia E.,Al-Dhfyan, Abdullah,Abdel-Aziz, Hatem A.

, p. 600 - 613 (2017/11/10)

Treatment of patients with triple-negative breast cancer (TNBC) is challenging due to the absence of well- defined molecular targets and the heterogeneity of such disease. In our endeavor to develop potent isatin-based anti-proliferative agents, we utiliz

Discovery of N -(4-(3-(2-Aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), A Highly Selective, Orally Bioavailable Inhibitor of Aurora Kinases with Activity against Multidrug-Resistant Cancer Cell Lines

Geuns-Meyer, Stephanie,Cee, Victor J.,Deak, Holly L.,Du, Bingfan,Hodous, Brian L.,Nguyen, Hanh Nho,Olivieri, Philip R.,Schenkel, Laurie B.,Vaida, Karina R.,Andrews, Paul,Bak, Annette,Be, Xuhai,Beltran, Pedro J.,Bush, Tammy L.,Chaves, Mary K.,Chung, Grace,Dai, Yang,Eden, Patrick,Hanestad, Kelly,Huang, Liyue,Lin, Min-Hwa Jasmine,Tang, Jin,Ziegler, Beth,Radinsky, Robert,Kendall, Richard,Patel, Vinod F.,Payton, Marc

, p. 5189 - 5207 (2015/08/03)

Efforts to improve upon the physical properties and metabolic stability of Aurora kinase inhibitor 14a revealed that potency against multidrug-resistant cell lines was compromised by increased polarity. Despite its high in vitro metabolic intrinsic cleara

Synthesis of 1,2-dihydro-1-oxophthalazin-4-yl trifluoromethanesulfonate and its application in the synthesis of 4-(aryl/heteroaryl/alkynyl)phthalazin-1(2H)-one

Dhage, Ganesh Raosaheb,Deshmukh, Santosh Rangnath,Thopate, Shankar Ramchandra

, p. 33377 - 33384 (2015/04/27)

The regioselective synthesis of 1,2-dihydro-1-oxophthalazin-4-yl trifluoromethanesulfonate (3a) has been reported. The reaction of Tf2O (2a) with phthalhydrazide (1a) provides a rapid access to 3a with an excellent yield and a high level of reg

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 51334-86-2